German Merck, Pfizer get FDA priority review for cancer drug

FRANKFURT (Reuters) – German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek approval to fight a rare and aggressive form of skin cancer with immunotherapy drug avelumab.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *